During the corresponding time, Axim Biotechnologies Inc recorded a revenue increase by 76.04 % year on year, sequentially revenue fell by -67.01 %. While revenue at the Axim Biotechnologies Inc 's corporate clients
Axim Biotechnologies Inc's Comment on Sales, Marketing and Customers
The company operates through a commercialization partner and focuses on diagnostic innovations protected by the USPTO. Its products include a rapid test for measuring neutralizing antibodies to SARS-CoV2, applicable to both infections and vaccines, providing a portable, low-cost, point-of-care solution. The company also develops rapid point-of-care tests for Human Monomeric Lacritin to diagnose eye diseases such as Blepharitis, Sjögren’s syndrome, and Dry Eye Disease. Additionally, it has created a laminated and looped tear sample collector designed to be cost-effective, easy to use, and less intimidating, intended to improve upon existing market options such as Quidel InflammaDry. The company is also developing rapid diagnostics for various cancers involving the enzyme QSOX1, which is over-expressed in multiple tumor types.
Biotech company AXIM Biotechnologies has entered into a critical partnership with a leading ...
Axim Biotechnologies Inc’s Comment on Sales, Marketing and Customers
The company operates through a commercialization partner and focuses on diagnostic innovations protected by the USPTO. Its products include a rapid test for measuring neutralizing antibodies to SARS-CoV2, applicable to both infections and vaccines, providing a portable, low-cost, point-of-care solution. The company also develops rapid point-of-care tests for Human Monomeric Lacritin to diagnose eye diseases such as Blepharitis, Sjögren’s syndrome, and Dry Eye Disease. Additionally, it has created a laminated and looped tear sample collector designed to be cost-effective, easy to use, and less intimidating, intended to improve upon existing market options such as Quidel InflammaDry. The company is also developing rapid diagnostics for various cancers involving the enzyme QSOX1, which is over-expressed in multiple tumor types.
Sources:
Axim Biotechnologies Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Axim Biotechnologies Inc’s corporate clients.
For your research, we’ve provided 9 tables on Axim Biotechnologies Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
